Sino-US biopharma CANbridge Pharmaceuticals (HKG: 1228) has announced the completion of patient enrollment in a Phase II trial for its pipeline candidate CAN008 (asunercept) in combination with temozolomide for the treatment of glioblastoma multiforme (GBM). The multi-center, randomized, placebo-controlled study, which is potentially registrational, has recruited a total of 117 newly diagnosed GBM patients. The trial aims to evaluate the safety and efficacy of asunercept during and after radiation therapy.
Asunercept’s Dual Mechanism of Action and Phase I Results
Asunercept is a CD95-Fc fusion protein that blocks the interaction between the CD95 ligand and its receptor. This molecule possesses a unique dual mechanism of action, which includes inhibiting the invasive growth and migration of tumor cells and reducing T-cell apoptosis, thereby enhancing immune recognition of cancer. Positive signs of efficacy were observed in an earlier Phase I trial for asunercept against GBM, with a 67% overall survival rate in the high-dose group and a median 17.95-month progression-free survival.
Anticipated Interim Data and Future Prospects
Interim data from the current Phase II study is expected in mid-2023. The completion of enrollment and the upcoming interim data are significant milestones for CANbridge Pharmaceuticals as they seek to advance CAN008 as a potential treatment for GBM, a highly aggressive form of brain cancer.-Fineline Info & Tech
